October 13, 2011 Shares of SANUWAVE Health Inc (OTC:SNWV) rose 20.9% to $2.14 +0.37 after the company announced publication of research which investigated the molecular changes of dermaPACE extracorporeal shock wave technology (ESWT) compared with hyperbaric oxygen therapy (HBOT) in diabetic foot ulcers. The study, titled Molecular Changes in Diabetic Foot Ulcers, by Ching-Jen Wang, M.D. of the Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine in Kaohsiung, Taiwan, appeared in the online edition of the European peer-reviewed journal Diabetes Research and Clinical Practice as an ePublication ahead of print. dermaPACE showed statistically significant increases in angiogenic and tissue regenerative molecular changes over HBOT in diabetic foot ulcers. dermaPACE demonstrated significant increases in angiogenesis (vWF, VEGF and eNOS) and cell proliferation (PCNA and EGF) and decreases in cell apoptosis (TUNEL), leading to tissue regeneration and wound repair (p<0.05), whereas the molecular changes after HBOT were not statistically significant. The study consisted of 39 patients (44 ulcers) in the ESWT group and 38 patients (40 ulcers) in the HBOT group, with similar demographic characteristics. The ESWT group received dermaPACE procedures twice per week for a total of six procedures over three weeks. The HBOT group received hyperbaric oxygen therapy daily for a total of 20 treatments, each lasting 90 minutes. Biopsies were performed from the periphery of the ulcer before and after treatment. Some recent trading activity prompted officials to look into the activities of one market maker in particular after Tuesday's session. It is unclear if the situation has been resolved, but there are definintely eyeballs monitoring the trading activities of the firm and trading action seemed to go much more smoothly on Wednesday.
Thursday, October 13, 2011
醫療無國界 瓜國13醫師進駐長庚特訓
【2011/10/13 聯合報】高雄長庚醫院院長陳肇隆去年率團赴瓜地馬拉義診，與瓜國結下情誼，今年更進一步提供20個名額，協助當地醫師精進醫術，首梯13人已經抵達，將展開為期一年的特訓，陳肇隆強調，醫療是救人的學問，不該藏私，如今我們可以讓別人來學習，更應該毫無保留地回饋國際社會。瓜地馬拉13名接受高雄長庚訓練的醫師日前隨總統科隆一起來台，上周六進駐長庚。高雄長庚除將傳授醫術外，還包辦學員食宿、機票，每個月提供每人2萬4千元獎學金，代訓計畫斥資800餘萬，展現醫療無國界的超然胸襟。高雄長庚自民國87年起，提供國際醫療人士來台學習肝臟移植機會，毫無保留地傾囊相授，以精進的醫術，默默地幫台灣推動「醫療外交」，受益的國家，遍及英、美、日、大陸、新加坡、菲律賓等國。 去年9月，高長院長陳肇隆親率院內主管級主治醫師赴瓜國義診，拜會醫師出身的瓜國副總統艾斯巴達（Rafael Espada）時，獲知瓜國有心成立國家移植中心，燃起協助的念頭，返台前主動釋出代訓計畫，讓瓜國萬分感動。 「醫療是救人的學問，不應該藏私」，陳肇隆說，台灣的醫療能有今天，是他們有機會到海外學習得來的成果，今天台灣可以讓別人學習，也該無保留地回饋國際社會。陳肇隆說，到醫療匱乏的地區義診，頂多只兩個禮拜，但當地卻有50周時間沒有醫療，與其送他們幾尾魚，不如送他們釣竿，教他們捕魚的技術。他指出，瓜國副總統本身是心臟科權威，在腎臟方面亦有權威人士，獨缺肝臟移植這一塊，也是最難的一塊，長庚希望協助他們補足缺角，這樣瓜國建立國家移植中心的團隊，就能更加完備。
醫療和保險的聯合論壇
醫療服務品質與保險產品的最佳醫療合作 2011/11/13 醫療保險產業中，醫療補助的產品方案、醫療順序、服務成本等一直都是持續關注的話題。尤其針對老年人市場。目前的少子化趨勢，意味著未來老年人需要自主照顧的機率越來越大，醫院健康維持機構等要如何提供患者便宜有效且可長期持續的醫療。醫療和保險機構要如何促進政府單位更加參與推廣僱用者以及市民協會的參與。透過從法律上、患者教育、保險公司和醫院間的經驗等多領域分析，將能有效地解決產業持續性的問題。針對此產業分析與討論的平台，日商環球訊息有限公司臺灣分公司(Global Information, Inc.)已開始接受申請報名，由IBC Asia主辦2011年11月於新加坡召開的"醫療和保險的聯合論壇(Healthcare & Insurance Collaboration Forum 2011)"。此一論壇深受台灣國際醫療協會(Taiwan Task Force for Medical Travel)所支持。是將保險及醫療服務提供的高階主管與相關的消費者/患者團體、醫生團、行政機關及政府代表拉在一起，最初且唯一的平台。此獨自的機會是讓主要利益攸關者為提供患者便宜有效且可長期持續的醫療，能以更密切合作的方法共享，改善、擴充亞洲的醫療部門，建構對彼此都有益的合作夥伴關係。會議中將針對醫療服務提供者、保險業者、以及最後對患者造成影響之最迫切議題，與上級主管級的演講者及意見領袖的洞察力和談話一起提供有活力、今日適時的主題。為了洞察新鮮的商務，改善純利潤，亦提供建構醫院和保險公司間合作所需工具，由國際性專家主持實踐且互動的研究會。這屆會議也同時與"2011年銀髮族醫療市場的展望(Silver Healthcare Market Outlook)"共同舉行。是有關對迅速高齡化的亞洲人口醫療需求提供服務，選擇該主要課題與龐大的市場機會，成為最初且最總括性的活動！ "2011年醫療和保險的聯合論壇"將迎來保險公司和醫院齊聚一堂，加深合作夥伴關係，強化活動，依然是亞洲最初且唯一的會議。並且透過保險及醫療業界領導者對話式的專題討論會、有益的演講及富有暗示的發表，採用成為爭論點的主題，能讓全部的有關人員強化有效果且成本效率佳的醫療合作。誠摯邀請醫療相關企業一同參與此一盛世。
MM-398 - Biotech's 5 key attacks on pancreatic cancer
October 13, 2011 — 9:26am ET | By Ryan McBride There are no approved therapies for patients with metastatic pancreatic cancer who fail treatment with the chemo drug gemcitabine. Potentially brightening the prospects for these patients, Merrimack Pharmaceutical's MM-398 has shown some promise in a mid-stage study and the developer now plans to usher the nano-drug into Phase III trial by the end of the year. The Cambridge, MA-based company's candidate is a formulation of the approved chemo drug irinotecan that is encapsulated in tiny liposomal particles to improve its properties for fighting cancer. In a recent single-arm Phase II trial, 40 pancreatic cancer patients on the drug had a median overall survival of 22.4 weeks. And one in 5 survived for more than a year, the company says. A sizable, $17 million to $22 million chunk of the firm's planned $172 million IPO would go toward the Phase III trial, which is expected to enroll 250 patients with metastatic pancreatic cancer and compare MM-398 with an existing treatment for this population that includes the chemo drugs 5-FU and leucovorin, according to an SEC filing. The trial will go a long way in determining whether Merrimack's drug will advance to the market for pancreatic cancer, and whether patients with limited options will have a new approved weapon against the aggressive tumors. After seeing the upbeat Phase II data on the drug, Merrimack went out and secured the Asian and European rights to the drug in May from PharmaEngine, which retained only rights to the experimental drug in Taiwan. Then, in July, the FDA granted the company orphan status for the treatment for the firm's target subset of pancreatic cancer patients, giving the firm 7 years of market exclusivity if the treatment is approved for this use. Merrimack, which is developing the drug for a variety of tumor types, gained ownership of the asset through its 2009 buyout of Hermes BioSciences, the candidate's original developer.
Posts
